Condition: Esophageal Cancer · Recurrence · DNA Methylation · Sponsor: City of Hope Medical Center
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.
This description comes directly from the study's public registry record.
Ajay Goel, PhD · 6262183452 · AJGOEL@COH.ORG
Koichi Takiguchi, PhD · 6262183452 · ktakiguchi@coh.org
Always discuss trial participation with your own doctor first.
| Nagoya University | Nagoya, Aichi-ken, Japan | Recruiting |
| Yamanashi Universiy | Chūō, Yamanashi, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06476067